Swiss drugmaker Roche is targeting a double‑digit share of the global weight‑loss market and aims to significantly narrow the lead held by Danish rival Novo Nordisk, its Chief Executive told Germany’s Handelsblatt business newspaper. The company’s push into the obesity treatment sector reflects intensifying competition with established players that dominate the rapidly growing area of GLP‑1 and related therapies.
Roche Chief Executive Thomas Schinecker said the company expects to secure at least a double‑digit percentage of the market and position itself among the top three competitors, challenging the long‑time market leadership of Novo Nordisk and other rivals. The comments underline Roche’s commitment to expanding its presence in treatments for obesity and metabolic disorders, a segment that has seen explosive growth and high demand as global rates of overweight and obesity rise.